244 related articles for article (PubMed ID: 25986914)
1. High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer.
Zhao SG; Jackson WC; Kothari V; Schipper MJ; Erho N; Evans JR; Speers C; Hamstra DA; Niknafs YS; Nguyen PL; Schaeffer EM; Ross AE; Den RB; Klein EA; Jenkins RB; Davicioni E; Feng FY
Prostate Cancer Prostatic Dis; 2015 Sep; 18(3):229-36. PubMed ID: 25986914
[TBL] [Abstract][Full Text] [Related]
2. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract][Full Text] [Related]
3. Evolving transcriptomic fingerprint based on genome-wide data as prognostic tools in prostate cancer.
Alshalalfa M; Schliekelman M; Shin H; Erho N; Davicioni E
Biol Cell; 2015 Jul; 107(7):232-44. PubMed ID: 25900404
[TBL] [Abstract][Full Text] [Related]
4. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
5. The Landscape of Prognostic Outlier Genes in High-Risk Prostate Cancer.
Zhao SG; Evans JR; Kothari V; Sun G; Larm A; Mondine V; Schaeffer EM; Ross AE; Klein EA; Den RB; Dicker AP; Karnes RJ; Erho N; Nguyen PL; Davicioni E; Feng FY
Clin Cancer Res; 2016 Apr; 22(7):1777-86. PubMed ID: 26631616
[TBL] [Abstract][Full Text] [Related]
6. Integrative clinical transcriptome analysis reveals TMPRSS2-ERG dependency of prognostic biomarkers in prostate adenocarcinoma.
Gerke JS; Orth MF; Tolkach Y; Romero-Pérez L; Wehweck FS; Stein S; Musa J; Knott MML; Hölting TLB; Li J; Sannino G; Marchetto A; Ohmura S; Cidre-Aranaz F; Müller-Nurasyid M; Strauch K; Stief C; Kristiansen G; Kirchner T; Buchner A; Grünewald TGP
Int J Cancer; 2020 Apr; 146(7):2036-2046. PubMed ID: 31732966
[TBL] [Abstract][Full Text] [Related]
7. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
[TBL] [Abstract][Full Text] [Related]
8. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.
Zhang Y; Yuan Y; Liang P; Zhang Z; Guo X; Xia L; Zhao Y; Shu XS; Sun S; Ying Y; Cheng Y
Oncotarget; 2017 Jul; 8(28):45459-45469. PubMed ID: 28525372
[TBL] [Abstract][Full Text] [Related]
10. Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer.
Rubicz R; Zhao S; Wright JL; Coleman I; Grasso C; Geybels MS; Leonardson A; Kolb S; April C; Bibikova M; Troyer D; Lance R; Lin DW; Ostrander EA; Nelson PS; Fan JB; Feng Z; Stanford JL
Mol Oncol; 2017 Feb; 11(2):140-150. PubMed ID: 28145099
[TBL] [Abstract][Full Text] [Related]
11. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
12. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
13. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer.
Rajan P; Stockley J; Sudbery IM; Fleming JT; Hedley A; Kalna G; Sims D; Ponting CP; Heger A; Robson CN; McMenemin RM; Pedley ID; Leung HY
BMC Cancer; 2014 Dec; 14():977. PubMed ID: 25519703
[TBL] [Abstract][Full Text] [Related]
14. Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Yu W; Li J; Wang Q; Wang B; Zhang L; Liu Y; Tang M; Xu G; Yang Z; Wang X; Zhang J; Liu Y; Shi G
Prostate; 2019 Aug; 79(11):1304-1315. PubMed ID: 31212367
[TBL] [Abstract][Full Text] [Related]
15. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
[TBL] [Abstract][Full Text] [Related]
16. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
18. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
19. Plasma proteasomal chymotrypsin-like activity correlates with prostate cancer progression.
Deng X; Zhou P; Wei X; Uhlman M; Lin Y; Lin X; Wu S; Diao P; Xie H; Liu J; Xie K; Tang P
Tumour Biol; 2015 Jun; 36(6):4115-21. PubMed ID: 25578495
[TBL] [Abstract][Full Text] [Related]
20. Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.
Zhao S; Geybels MS; Leonardson A; Rubicz R; Kolb S; Yan Q; Klotzle B; Bibikova M; Hurtado-Coll A; Troyer D; Lance R; Lin DW; Wright JL; Ostrander EA; Fan JB; Feng Z; Stanford JL
Clin Cancer Res; 2017 Jan; 23(1):311-319. PubMed ID: 27358489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]